Gabriel L. Hendricks, Ph.D.

Patent Agent

Gabriel works on patents within the Biotechnology sector.

Gabriel Hendricks Portrait

Gabriel’s work includes patent prosecution in the biotechnology sector, including cancer biology and therapeutics, immunology, small molecule therapeutics, and research tools.

Gabriel has managed all aspects of patent portfolios across various technologies, including US and foreign patent applications for mechanical, chemical, software, and biology inventions. Prior to joining ArentFox Schiff, Gabriel was a patent agent at a mid-sized law firm in Boston.

Gabriel received his PhD in Biomedical Research from the University of Massachusetts Medical School. His research focused on the immunology of RNA and DNA viruses and antiviral therapeutics against these viruses. At UMass, he worked on novel decoy liposomes that could be produced on demand with different viral receptors, thereby acting as a molecular sink and infection dead-end. Gabriel has authored and presented numerous scientific publications in the fields of viral immunology, antivirals, antimicrobials, antifungals, and neuroscience.

Publications, Presentations & Recognitions

Publications

  • Kim W, Zhu W, Hendricks GL, Van Tyne D, Steele AD, Keohane CE, Fricke N, Conery AL, Shen S, Pan W, Lee K, Rajamuthiah R, Fuchs BB, Vlahovska PM, Wuest WM, Gilmore MS, Gao H, Ausubel FM, Mylonakis E. A new class of synthetic retinoid antibiotics effective against bacterial persisters. Nature. 2018 Apr 5;556(7699):103-107. doi: 10.1038/nature26157. Epub 2018 Mar 28. PMID: 29590091; PMCID: PMC6462414.
  • Kim W, Zou G, Hari TPA, Wilt IK, Zhu W, Galle N, Faizi HA, Hendricks GL, Tori K, Pan W, Huang X, Steele AD, Csatary EE, Dekarske MM, Rosen JL, Ribeiro NQ, Lee K, Port J, Fuchs BB, Vlahovska PM, Wuest WM, Gao H, Ausubel FM, Mylonakis E. A selective membrane-targeting repurposed antibiotic with activity against persistent methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U S A. 2019 Aug 13;116{33):16529-16534. doi: 10.1073/pnas.1904700116. Epub 2019 Jul 29. PMID: 31358625; PMCID: PMC6697817.
  • Kim W, Hendricks GL, Tori K, Fuchs BB, Mylonakis E. Strategies against methicillin-resistant Staphylococcus aureus persisters. Future Med Chem. 2018 Apr 1;10(7):779-794. doi:10.4155/fmc-2017-0199. Epub 2018 Mar 23. PMID: 29569952; PMCID: PMC6077763.
  • Kim W, Hendricks GL, Lee K, Mylonakis E. An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs. Expert Opin Drug Discov. 2017 Jun;12(6):625-633. doi: 10.1080/17460441.2017.1319358. Epub 2017 Apr 21. PMID: 28402221.
  • Hendricks G, Mylonakis E. Expanding the nematode model system: The molecular basis of inflammation and infection recovery in C. elegans. Virulence. 2017 Apr 3;8(3):244-245. doi: 0.1080/21505594.2016.1239011. Epub 2016 Sep 26. PMID: 27668316; PMCID: PMC5411239.
  • Fuchs BB, Li Y, Li D, Johnston T, Hendricks G, Li G, Rajamuthiah R, Mylonakis E. Micafungin Elicits an lmmunomodulatory Effect in Galleria mellonella and Mice. Mycopathologia. 2016 Feb;181 (1-2):17-25. doi: 10.1007 /s11046-01 5-9940-z. Epub 2015 Sep 18. Erratum in: Mycopathologia. 2016 Feb;181(1-2):27. PMID: 26384671; PMCID: PMC4676791.
  • Hendricks GL, Velazquez L, Pham S, Qaisar N, Delaney JC, Viswanathan K, Albers L, Comolli JC, Shriver Z, Knipe DM, Kurt-Jones EA, Fygenson DK, Trevejo JM, Wang JP, Finberg RW. Heparin octasaccharide decoy liposomes inhibit replication of multiple viruses. Antiviral Res. 2015 Apr;116:34-44. doi: 10.1016/j.antiviral.2015.01 .008. Epub 2015 Jan 28. PMID: 2563771 O; PMCID: PMC4988063.
  • Hendricks GL, Weirich KL, Viswanathan K, Li J, Shriver ZH, Ashour J, Ploegh HL, Kurt-Jones EA, Fygenson DK, Finberg RW, Comolli JC, Wang JP. Sialylneolacto- N-tetraose c (LSTc)­bearing liposomal decoys capture influenza A virus. J Biol Chem. 2013 Mar 22;288(12):8061-8073. doi: 10.1074/jbc.M112.437202. Epub 2013 Jan 28. PMID: 23362274; PMCID: PMC3605625.
  • Narayan K, Waggoner L, Pham ST, Hendricks GL, Waggoner SN, Conlon J, Wang JP, Fitzgerald KA, Kang J. TRIM13 is a negative regulator of MDA5-mediated type I interferon production. J Viral. 2014 Sep;88(18):10748-57. doi: 10.1128/JVl.02593-13. Epub 2014 Jul 9. PMID: 25008915; PMCID: PMC4178852.
  • Kline DD, Hendricks G, Hermann G, Rogers RC, Kunze DL. Dopamine inhibits N-type channels in visceral afferents to reduce synaptic transmitter release under normoxic and chronic intermittent hypoxic conditions. J Neurophysiol. 2009 May;101 (5):2270-8. doi: 10.1152/jn.91304.2008. Epub 2009 Feb 25. PMID: 19244351; PMCID: PMC2681443.

Presentations

  • “Combining Research Science & Intellectual Property as a Patent Agent,” Speaker, The University of Massachusetts Medical School, Jan. 2019
  • Industries
    Practices
  • Bar & Court Admissions
    • US Patent and Trademark Office
  • Education
    University of Massachusetts Medical School, PhD
    Oberlin College, BA